[Retrospective analysis of surgical treatment for metastases in humerus of 59 cases].
To evaluate different operative treatment options for patients with metastases of the humerus focusing on surgical procedures, complications, function, and survival rate. From 2000 to 2009, 62 bone metastases of the humerus in 59 patients were surgically treated in our institutions. Histological types were of lung (n=19), myeloma (n=10), breast (n=8), kidney (n=5), gastrointestinal tract (n=2), thyroid (n=2), prostate (n=1), bile duct (n=1), larynx (n=1), ovarian (n=1), melanoma (n=1) and unknown tumors (n= 8). Severe osteolytic lesions close to the shoulder and elbow joint were treated with resection and endoprosthetic replacement (n=32). Twenty-eight metasteses were stabilized by intramedullary locked nailing (17 cases) or plate/screws (11 cases) with polymethylmethacrylate-assisted reconstruction. The remaining 2 lesions were treated with amputation because of wide tumor contaminations after pathological fracture. Mirels' rating system was used to predict the risk of pathological fracture. The function of the upper limb was assessed using the Musculoskeletal Tumor Society (MSTS) rating scale and survival rate was retrospectively analyzed. The mean survival time of patients after surgery was 9.6 months. The mean Mirels' score for impending pathologic fractures was 9.3. Complications of endoprosthetic replacement recorded included disease relapse (n=2) and soft tissue infection (n=1), whereas, for intramedullary locked nailing and plate/screws fixation, there were two cases of local recurrence, one case of plate/screw break and one case of radial nerve palsy. The mean MSTS score for the follow-up was 71% for endoprosthesis and 75.1% for locked intramedullary nailing or plate/screws fixation. Immediate stability and pain relief were the main purpose of surgical procedures to treat humerus metastases. Radiotherapy was only a local treatment; however systemic therapies, such as chemotherapy, hormonotherapy and bisphophonate play a critical role in increasing survival rate of bone metastatic patients.